Lee Munson, president and CIO at Portfolio Wealth Advisors, joins CNBC’s ‘Power Lunch’ to discuss outlooks on three stocks: ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in ...

The drugmaker Ely Lilly ( LLY -4.93%) has had a very successful run over the long run. Shares currently trade around $818 and are up 20,030% over the past 40 years. The stock has also performed well ...

Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...

Conditions are getting a bit more challenging for the drugmaker.

Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales ...

Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 23.80% higher than today’s price of $832.00.

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

But in the last few years, Eli Lilly was a great investment — mostly due to the success of Mounjaro and Zepbound. Nevertheless, the stock seems expensive — also when compared to Novo Nordisk ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...